The multiple sclerosis drugs market will register a CAGR of close to 6% by 2023

Tuesday, March 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 11, 2019 /PRNewswire/ -- About this market Globally, the prevalence of multiple sclerosis has increased

due to genetic and environmental factors. Another reason which could be attributed to the increasing prevalence is the advances in diagnostic techniques in this therapy area. The prevalence of autoimmune diseases such as type 1 diabetes and certain infections
such as infectious mononucleosis also increases the risk of multiple sclerosis. In 2008, the global prevalence of multiple sclerosis was estimated to be 0.031%, which increased to 0.032% in 2013. The prevalence of multiple sclerosis in Europe is also high. High disease prevalence drives the demand for drugs, thereby driving the growth of the market. Our analysts have predicted that the multiple sclerosis drugs market will register a CAGR of close to 6% by 2023.Read the full report: https://www.reportlinker.com/p05751907 Market Overview Strong drug pipeline With the increase in the prevalence of multiple sclerosis, there is a high unmet need for a strong pipeline of disease-modifying drugs. Current drugs for multiple sclerosis slow down the disease progression, but in many patients' responses to drugs are often variable and suboptimal. Ongoing R&D for the development of new drugs has resulted in the development of a strong drug pipeline for the treatment of multiple sclerosis. Therefore, the drug development initiatives by companies are expected to dive the market in the forecast period. Side effects of multiple sclerosis drugs The side effects associated with multiple sclerosis drugs can range from mild to serious. Therefore, side effects associated with these drugs can lead to low patient compliance and may hinder the growth of the global multiple sclerosis drugs market. For the detailed list of factors that will drive and challenge the growth of the multiple sclerosis drugs market during the 2019-2023, view our report. Competitive Landscape The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Read the full report: https://www.reportlinker.com/p05751907 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-multiple-sclerosis-drugs-market-will-register-a-cagr-of-close-to-6-by-2023-300810298.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store